Alpha DNA Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.6M |
| 2 |
EOG Resources
EOG
|
+$2.56M |
| 3 |
Chevron
CVX
|
+$2.51M |
| 4 |
Kenvue
KVUE
|
+$1.8M |
| 5 |
NextEra Energy
NEE
|
+$1.79M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$3M |
| 2 |
PPG Industries
PPG
|
+$2.06M |
| 3 |
Colgate-Palmolive
CL
|
+$1.74M |
| 4 |
McDonald's
MCD
|
+$1.67M |
| 5 |
RTX Corp
RTX
|
+$1.53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.66% |
| 2 | Financials | 12.3% |
| 3 | Healthcare | 9.54% |
| 4 | Energy | 5.49% |
| 5 | Consumer Staples | 5.4% |
Similar funds
Alpha DNA Investment Management's Q4 2023 Portfolio in Review
As of Q4 2023, Alpha DNA Investment Management held 248 positions worth $256M, up 5% from $244M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Alpha DNA Investment Management withdrew a net $14.2M in Q4 2023, closing 65 positions and reducing 67 holdings. Its most notable exit was Eli Lilly, an estimated $3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 13% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Alpha DNA Investment Management opened a new position in Kenvue worth $1.93M.
- Alpha DNA Investment Management's largest Q4 2023 buy was Kenvue: 89,868 shares worth $1.93M.
- Alpha DNA Investment Management added most to Microsoft in Q4 2023, an estimated $2.6M increase.
- Alpha DNA Investment Management's biggest Q4 2023 reduction was PPG Industries, cutting an estimated $2.06M.
- Alpha DNA Investment Management fully exited Eli Lilly in Q4 2023, selling an estimated $3M.
- Alpha DNA Investment Management's ten largest holdings make up 47% of its $256M portfolio in Q4 2023.
- Alpha DNA Investment Management opened 79 new positions and closed 65 in Q4 2023.
- Alpha DNA Investment Management's portfolio value rose 5% quarter-over-quarter to $256M.
Based on Alpha DNA Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.